Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of edoxaban as compared with warfarin in patients with atrial fibrillation is ...

Edoxaban is an oral, reversible, direct factor Xa inhibitor that was shown to be noninferior to a vitamin K antagonist (warfarin) in the prevention of stroke and other thromboembolic events, with ...

Edoxaban is administered once daily, whereas the approved pediatric dosing for other direct oral anticoagulants (DOACs) ranges from twice daily to three times per day, he noted.

Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR. New England Journal of Medicine, 2021; DOI: 10.1056/NEJMoa2111016; Cite This Page: MLA; APA; Chicago; ...

Edoxaban, an oral anticoagulant, was equally or more effective than warfarin in reducing the risk of stroke and blood clots for patients after heart valve replacement surgery, according to ...

Edoxaban, a reversible and direct inhibitor of factor Xa, is used to reduce the risk for stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF). It is also used to ...

Edoxaban was found to be noninferior to warfarin in patients with AF undergoing TAVR, a population that warranted further study. In places such as East Asia where edoxaban is used, it remains a ...

However, major bleeding rates were lower for apixaban, driven by differences in gastrointestinal bleeding and other nonspecified bleeding (45.57 vs 31.21 per 1,000 person-years; adjusted HR 1.42 ...

Male patients made up 51.3% and 62.4% of the edoxaban and warfarin arms, respectively. About one in five patients had AF, and the vast majority of patients had aortic valve surgery. About one-third of ...

Edoxaban monotherapy reduced net adverse clinical events compared with edoxaban plus a single antiplatelet agent, when used as long-term antithrombotic therapy, in patients with high-risk atrial ...

4 Consideration of the evidence. The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of edoxaban, having considered evidence on the nature of non‑valvular atrial ...